Table 2.
Association of first-line treatments with clinical outcomes according to unadjusted and adjusted Cox regression models
| Clinical outcome | Pembrolizumab + axitinib |
Ipilimumab + nivolumab |
TKI monotherapy |
|||
|---|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
| Time on treatment | ||||||
| Unadjusted HR | 0.36 (0.30–0.45) | <0.0001 | 0.65 (0.56–0.74) | <0.0001 | Reference | |
| Adjusted HRa | 0.37 (0.30–0.45) | <0.0001 | 0.63 (0.54–0.73) | <0.0001 | Reference | |
| Unadjusted HR | 0.56 (0.46–0.70) | <0.0001 | Reference | 1.55 (1.35–1.78) | <0.0001 | |
| Adjusted HRa | 0.59 (0.47–0.72) | <0.0001 | Reference | 1.59 (1.38–1.84) | <0.0001 | |
| TTNT | ||||||
| Unadjusted HR | 0.53 (0.42–0.66) | <0.0001 | 0.90 (0.78–1.05) | 0.1711 | Reference | |
| Adjusted HRa | 0.53 (0.42–0.67) | <0.0001 | 0.86 (0.74–1.01) | 0.0739 | Reference | |
| Unadjusted HR | 0.59 (0.47–0.74) | <0.0001 | Reference | 1.11 (0.96–1.29) | 0.1711 | |
| Adjusted HRa | 0.61 (0.49–0.77) | <0.0001 | Reference | 1.16 (0.99–1.36) | 0.0739 | |
| Overall survival | ||||||
| Unadjusted HR | 0.77 (0.57–1.04) | 0.0896 | 0.96 (0.78–1.17) | 0.6735 | Reference | |
| Adjusted HRa | 0.79 (0.58–1.08) | 0.1371 | 0.94 (0.76–1.17) | 0.6096 | Reference | |
| Unadjusted HR | 0.81 (0.60–1.08) | 0.1511 | Reference | 1.04 (0.86–1.28) | 0.6735 | |
| Adjusted HRa | 0.84 (0.62–1.13) | 0.2454 | Reference | 1.06 (0.85–1.32) | 0.6096 | |
CI = confidence interval; HR = hazard ratio; TKI = tyrosine kinase inhibitor; TTNT = time to next treatment.
a
Adjusted analysis accounted for age, sex, race, tobacco use, body mass index, Eastern Cooperative Oncology Group performance status, histology, and International Metastatic Renal Cell Carcinoma Database Consortium risk score.